ストックスクリーナーアプリを入手
0.24
24.51%
-0.0713
Zyversa Therapeutics Inc (ZVSA) 最新ニュース
ZyVersa Therapeutics approved for trading on OTCQB Venture Market By Investing.com - Investing.com India
ZyVersa Therapeutics Stock Approved for OTCQB Listing - TipRanks
Custom watchlist performance reports with ZyVersa Therapeutics Inc.Free Swing Setup With Technical Confirmation - Newser
Visual analytics tools that track ZyVersa Therapeutics Inc. performanceFree Reliable Alerts for Daily Stock Movers - Newser
Reversal indicators forming on ZyVersa Therapeutics Inc. stock Monthly Long-Term Market Recap and Summary - Newser
When is ZyVersa Therapeutics Inc. stock expected to show significant growthMarket-leading growth rates - jammulinksnews.com
What makes ZyVersa Therapeutics Inc. stock price move sharplyDiscover stocks with strong growth potential - jammulinksnews.com
Is it the right time to buy ZyVersa Therapeutics Inc. stockHigh-impact investment strategies - jammulinksnews.com
What institutional investors are buying ZyVersa Therapeutics Inc. stockDouble or triple returns - jammulinksnews.com
Is ZyVersa Therapeutics Inc. a growth stock or a value stockUnlock exclusive trading tools and resources - jammulinksnews.com
Key External Factors That Drive ZyVersa Therapeutics Inc. Stock Price MovementsRisk Managed Trading Strategy - Newser
Is ZyVersa Therapeutics Inc. a Top Dividend Stock to Watch in 2025Big Return Stock Tips - Newser
ZyVersa Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What analysts say about ZyVersa Therapeutics Inc. stockExceptional profit potential - Autocar Professional
Is ZyVersa Therapeutics Inc. a good long term investmentRapid-fire capital growth - Autocar Professional
What drives ZyVersa Therapeutics Inc. stock priceRapidly growing investment returns - jammulinksnews.com
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter - GlobeNewswire
ZyVersa secures $12 million in financing to advance kidney disease trials - Investing.com Canada
ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq
ZyVersa Therapeutics Raises $12M to Accelerate Breakthrough Kidney and Inflammatory Disease Treatments - Stock Titan
ZVSA’s Market Whiplash: -93.65% YTD Decline, -52.27% Plunge in 30 Days - investchronicle.com
Why ZyVersa Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com India
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move - TipRanks
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market By Investing.com - Investing.com South Africa
How ZyVersa Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
ZyVersa Therapeutics (NASDAQ:ZVSA) Rating Increased to Hold at Wall Street Zen - Defense World
ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis - MarketBeat
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator?? VAR 200 in A Patient with ApoCII Amyloidosis - MarketScreener
Why Did ZyVersa Therapeutics Plunge 10% Despite Funding Boost? - AInvest
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 17.4% – Time to Buy? - Defense World
ZyVersa announces warrant inducement transaction for $2M in gross proceeds - TipRanks
ZyVersa Therapeutics Supports FDA-Authorized Emergency - GlobeNewswire
0.47%
0.71%
大文字化:
|
ボリューム (24 時間):